BIO Consulting Group is a leading consultancy firm dedicated to providing a comprehensive range of services to clients in the biotechnology, synthetic biology, pharmaceutical, and life sciences industries. With a team of highly experienced professionals, we pride ourselves on our ability to leverage in-depth knowledge and expertise to deliver innovative solutions that drive success for our clients.
Our team consists of industry experts, researchers, and professionals with diverse backgrounds, including molecular biology, genetics, bioinformatics, business strategy, and more. This allows us to offer a multidisciplinary approach that combines scientific knowledge with practical business insights to address the unique challenges faced by companies in the life sciences sector.
At BIO Consulting Group, our mission is to assist our clients in overcoming challenges, achieving their goals, and advancing scientific discoveries. We are committed to providing high-quality, customized services that include research and development consulting, business strategy and market analysis, regulatory affairs and compliance, intellectual property and technology transfer, product development and manufacturing, clinical trial management and monitoring, grant writing and funding support, and training and education.
In addition, we offer specialized consulting services in areas such as sustainability and environmental management, as well as bioinformatics consulting, to ensure that our clients can harness cutting-edge technology and adopt sustainable practices in their operations.
At BIO Consulting Group, we believe in building long-term relationships with our clients, providing them with the support they need at every stage of their business journey. Our client-centric approach, combined with our extensive industry experience and dedication to innovation, makes us a trusted partner for companies looking to excel in the rapidly evolving life sciences landscape.
Together, let's advance the frontiers of science and create a more sustainable future.
Mariano Belaich
Mariano Belaich has over 30 years of experience in Biotechnology and Synthetic Biology, specializing in Viral and Non-Viral Vaccines, Gene and Cell Therapy development, and advanced nucleic acid-based technologies. As the Co-founder and Chief Scientific Officer of SYTE.bio, a Synthetic Biology company focused on creating next-generation DNA and RNA-based Vaccines and Therapies for both Human and Veterinary Medicine, Mariano leads a research team driving innovation in the field. His strong focus on execution has enabled him to deliver impactful scientific results efficiently.
In addition to his leadership at SYTE.bio, Mariano is the Director of the Laboratory of Genetic Engineering and Cellular and Molecular Biology at the National University of Quilmes (UNQ) and serves as an Associate Professor at both UNQ and Favaloro University. Mariano is also leads at BioConsulting Group, a global consulting firm in Biotechnology and Synthetic Biology, and a researcher at the National Scientific and Technical Research Council (CONICET) in Argentina. He also serves as the Vice President of the Argentina Synthetic Biology Association, further solidifying his leadership in the field. With a wealth of knowledge in evaluating scientific value, guiding research, and developing projects from discovery through to clinical applications, Mariano has been instrumental in advising on vaccine and therapy development for multiple biotech start-ups.
Mariano’s influence in the scientific community is further evidenced by his mentoring of 8 PhD students and 18 undergraduate theses, as well as his leadership in various research grants. He has authored 42 academic journal articles and book chapters, alongside over 150 conference presentations in the fields of agricultural and human health biotechnology. His diverse background in Synthetic Biology includes developing treatments for Melanoma, Sarcoma, Anemia and Diabetes. He is also involved in the development of vaccines for diseases such as rabies, COVID, dengue, and hantavirus, utilizing both viral and non-viral delivery systems.
Mariano’s areas of expertise include Genetic Engineering, Molecular Biology, and Synthetic Biology, with a focus on Viral and Non-Viral Vaccines and Gene Therapies. He also has a robust background in project evaluation and management, particularly within academic and research settings. Fluent in multiple languages and nurtured by a multicultural academic background, Mariano has extensive experience in R&D, academic program management, and strategic consulting.
Mariano holds a Bachelor’s degree in Biotechnology and a Ph.D. in Basic and Applied Sciences from the National University of Quilmes (UNQ). He is a well-established figure in the field, actively contributing to the advancement of human and animal health through Synthetic Biology.
Martin Williams
Martin Williams has over 20 years of experience in Biotechnology and Synthetic Biology, specializing in Viral and Non-Viral Vaccines, Cell, and Gene Therapies development, and cutting-edge nucleic acid-based technologies. As the founder and CEO of SYTE.bio, a Synthetic Biology Company focused on advancing next-generation DNA and RNA-based Vaccines and Therapies for both Human and Veterinary Medicine, Martin leads a dedicated team that drives innovation in the field. His sharp focus on execution has enabled him to deliver impressive results swiftly.
In addition to his leadership role at SYTE.bio, Martin is the CEO and Founder of Healix Instruments, a medical device company, and served as Interim Chief Scientific Officer for Athergen, a Boston-based company specializing in Cell Reprogramming Technology using miRNA. Martin’s strategic insights extend further, as he is the founder and principal of BioConsulting Group, a global consulting firm specializing in Biotechnology and Synthetic Biology. He also lends his expertise as a Strategic Consultant at BioStrategy Advisors LLC, a consultancy firm in Boston. He has been instrumental in assessing the scientific value of technologies, guiding research and development from discovery through pre-clinical and clinical stages, and advising start-up founders on therapies and device development, AI integration, and pipeline prioritization.
Martin’s influence in the field is further solidified as the founder and President of the Argentinean Synthetic Biology Association, the first organization of its kind in Latin America. He also serves as a Professor of Genetic Engineering at Universidad Favaloro in Argentina. His diverse background in Synthetic Biology includes work on cancer treatments for Melanoma and Sarcoma, involving DNA, RNA, oncolytic viruses, insect and bacterial engineered viruses, as well as diseases such as Type 1 Diabetes, Type 2 Diabetes, and Anemia. He has also been involved in the development of vaccines for diseases such as rabies, COVID, dengue, and hantavirus.
A highly skilled expert, Martin’s areas of expertise include Biotechnology, Molecular Biology, Synthetic Biology, Genetic Engineering, Viral and Non-Viral Vaccines Gene Therapies Development. He is also skilled in Patent Analysis and Writing, having been granted patents on groundbreaking technologies. His mission is to drive innovation in healthcare by creating groundbreaking medical solutions and offering strategic advice that fosters the growth of biotechnology projects. Fluent in two languages and with a rich multicultural background, Martin has extensive experience in Research and Development, Management, Corporate Strategy, Business Development, and Business Agreements.
Martin holds a degree in Biotechnology and a PhD in Synthetic Biology. He is also a certified Clinical Analysis Laboratory Technician and holds postgraduate degrees in Pharmaceutical Biotechnology and Synthetic Biology, alongside certificates in Bioinformatics, Immunoinformatics, Programming, and Graphic Design.
Carolina Alarco has over 30 years of experience in the biopharmaceutical industry in Massachusetts, specializing in building life sciences companies, strategic market development for rare diseases and innovative technologies, and successfully launching transformative therapies globally. As the Founder and Principal at Bio Strategy Advisors LLC, a strategic business consulting firm, Carolina leads a dedicated team that drives innovation in the biotech sector by focusing on start-up formation, corporate strategy, investor readiness, strategic partnerships, and geographical expansion. Her sharp focus on execution has enabled her to achieve significant results in the industry.
In addition to her leadership role at Bio Strategy Advisors, Carolina is a Strategic Consultant at BioConsulting Group, leveraging her expertise in the Biotech and Medtech industry. She is also a Founding Venture Partner at AccelHUB Venture Partners, specializing in early seed and angel investing and providing inbound U.S. soft landing for Latin American companies. In this role, she plays a central part in pitch evaluation, selection processes, deal execution, and the initial build of high-quality startups.
Carolina’s influence in the field is further solidified through her philanthropic focus and service on several non-profit boards. She is the Co-Founder and Co-Chair of Latinos in Bio, a 501(c)(3) non-profit organization of Latino professionals in BioPharma, where she fosters diversity and inclusion within the industry. She serves on the Board of MassBio, the Massachusetts Biotechnology Council, and has been recently elected to the Mass General Physicians Organization (MGPO) Board of Trustees. Additionally, Carolina serves on the Greater Boston Chamber of Commerce Women’s Advisory Board, the Massachusetts STEM Advisory Council, and the Latino Council at Boston Children’s Hospital.
Previously, Carolina spent 15 years at Genzyme, where she was a Vice President until its acquisition by Sanofi in 2011. She then served as President at Aegerion Pharmaceuticals and at Novelion Therapeutics until their respective exits. An active angel investor, she is involved with Walnut Ventures, TBD Angels, The Longevity Investors Network, and AccelHUB Ventures. Carolina also serves on the boards of several private biotech companies, including SYTE.bio, NED Biosystems, and Dione Antibiotics, as well as on the Board of Advisors of Eastern Bank, a publicly traded bank in Boston.
Carolina holds a Bachelor of Science in Business Administration from the University of Lima and a Graduate Degree in Business and Management from Harvard University. Fluent in English and Spanish, and with a rich multicultural background, she brings extensive experience in management, corporate strategy, business development, and investment to the biotech industry. Her mission is to drive innovation in healthcare by creating groundbreaking medical solutions and offering strategic advice that fosters the growth of biotechnology projects.
Carolina Alarco
Juan Pablo Tevini
Juan Pablo Tevini is a dedicated legal professional with over a decade of experience in the legal sector in Buenos Aires, Argentina. Specializing in civil, commercial, and labor law, as well as human rights with a focus on elder law, he brings a proactive and dynamic approach to legal management and services. As the Legal Advisor at Syte.Bio, a biotechnology startup focused on developing gene therapies for treating diseases in humans and animals, Juan Pablo plays a crucial role in negotiating with public and private entities, analyzing contracts, developing proposals, and crafting sales strategies.
In addition to his role at SYTE.Bio, Juan Pablo is a Legal Consultant at BioConsulting Group, where he leverages his expertise to support our clients projects. His keen business acumen and focus on execution have enabled him to achieve significant results in the legal field.
Juan Pablo’s influence extends into academia and philanthropy. He serves as a Professor in the Department of Private Law at the University of Buenos Aires, fostering the next generation of professionals. He has served as a member of the Gerontological Advisory Council and has organized multiple seminars and conferences.
Juan Pablo holds a Law Degree from the University of Buenos Aires, with specialized knowledge in civil and commercial law, human rights oriented towards elder law, and labor law. He has completed Postraduate courses and workshops at institutions such as Harvard University, focusing on negotiation techniques and conflict resolution. With a rich multicultural background, he brings extensive experience in legal management, strategic advice, and client relations to the Biotech and Medtech Industry. His mission is to achieve positive results in any scenario by demonstrating responsibility, commitment, adaptability, and a strong capacity for teamwork, driving innovation in Legal Services.
